Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells

Leukemia Research

Volumn 35, Issue 5, 2011, Pages

  Al Ustwani, Omar ^a   Francis, Jawad ^a   Wallace, Paul K ^a   Ambrus, Julian ^b   Wetzler, Meir ^a  

^a Cancer Institute   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZACITIDINE; ANTINUCLEAR ANTIBODY; AZACITIDINE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTHRALGIA; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; DYSPNEA; FEMALE; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; LETTER; LEUKOPENIA; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RASH; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREMOR;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; AUTOIMMUNE DISEASES; AZACITIDINE; BLOOD CELL COUNT; DOWN-REGULATION; HUMANS; HUNTINGTON DISEASE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES, REGULATORY;

EID: 79954604703     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.12.015     Document Type: Letter

References (10)

1. Voulgarelis M., Giannouli S., Ritis K., Tzioufas A.G. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 2004, 34(October (10)):690-700.
2. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110(August (3)):847-850.
3. Kiladjian J.J., Visentin G., Viey E., Chevret S., Eclache V., Stirnemann J., et al. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 2008, 93(March (3)):381-389.
4. Grant J., Bourcier K., Wallace S., Pan D., Conway A., Seyfert-Margolis V., et al. Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients. Cytometry B Clin Cytom 2009, 76(March (2)):69-78.
5. Gottenberg J.E., Lavie F., Abbed K., Gasnault J., Le Nevot E., Delfraissy J.F., et al. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjogren's syndrome. J Autoimmun 2005, 24(May (3)):235-242.
6. Azab N.A., Bassyouni I.H., Emad Y., Abd El-Wahab G.A., Hamdy G., Mashahit M.A. CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol 2008, 127(May (2)):151-157.
7. Cepika A.M., Marinic I., Morovic-Vergles J., Soldo-Juresa D., Gagro A. Effect of steroids on the frequency of regulatory T cells and expression of FOXP3 in a patient with systemic lupus erythematosus: a two-year follow-up. Lupus 2007, 16(5):374-377.
8. Cao D., Malmstrom V., Baecher-Allan C., Hafler D., Klareskog L., Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003, 33(January (1)):215-223.
9. Habibagahi M., Habibagahi Z., Jaberipour M., Aghdashi A Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus. Rheumatol Int 2010, (April).
10. Barreto M., Ferreira R.C., Lourenco L., Moraes-Fontes M.F., Santos E., Alves M., et al. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol 2009, 10:5.